Table 1.
Cell line | Sensitivity to nocodazole | p53 status | Mitotic spindle checkpoint* | Reference for p53 status |
---|---|---|---|---|
A-427 | Resistant | Wild type | Impaired | 29 |
PC-1 | Resistant | Wild type | Impaired | 30 |
SK-LU-1 | Resistant | His to Arg (codon 193) | Impaired | 31 |
Calu-1 | Resistant | Homozygous deletion | Partially impaired | 30 |
ACC-LC-176 | Resistant | Wild type | Normal | 30 |
QG56 | Resistant | Pro to Ser (codon 249) | Normal | 30 |
NCI-H460 | Sensitive | Wild type | Normal | 30 |
SBC-3 | Sensitive | Wild type | Normal | 32 |
A549 | Sensitive | Wild type | Normal | 31 |
PC-10 | Sensitive | Gly to Cys (codon 245) | Normal | 30 |
SK-MES-1 | Sensitive | Glu to stop (codon 298) | Normal | 30 |
HCT116 | Sensitive | Wild type | Normal | 30 |
HeLa | Sensitive | Wild type | Normal | 33 |
*Mitotic spindle checkpoint response was examined as described previously and graded for mitotic indices at 18 hours after the initiation of nocodazole treatment: impaired, <20%; Partially impaired, 20 to 40%; normal, >40%.